BioSpace News Archive

Medtronic plc, a global leader in healthcare technology, announced it will participate in the 43rd annual Cowen healthcare conference on Monday, March 6, 2023.

Black people are receiving medications for dementia less often than white people, according to a preliminary study released February 26, 2023, that will be presented at the American Academy of Neurology’s 75th Annual Meeting being held in person in Boston and live online from April 22-27, 2023.

Galapagos NV (Euronext & NASDAQ: GLPG) will present new data at the European Crohn’s and Colitis Organization (ECCO) annual congress taking place from 1-4 March 2023.

Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced that management will participate in both a panel discussion and a fireside chat at the Cowen 43rd Annual Health Care Conference, being held March 6-8, 2023, in Boston, Massachusetts.

Gritstone bio, Inc. announced that Andrew Allen, M.D., Ph.D., Gritstone’s Co-founder, President and Chief Executive Officer will participate in the “Novel Immuno-Oncology” panel at the Cowen 43rd Annual Healthcare Conference on March 6, 2023.

Gain Therapeutics, Inc. presented new pre-clinical data from its Gaucher disease program in a poster presentation at the 19th Annual WORLDSymposium held February 22–26, 2023, in Orlando, Florida.

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in a fireside chat at 43rd Annual Cowen Health Care Conference on Monday, March 6, 2023, at 10:30 a.m. ET.

Ardelyx, Inc. today announced that Mike Raab, president and chief executive officer of Ardelyx, will participate in a GI/Microbiome panel discussion at the Cowen 43rd Annual Health Care Conference on Monday March 6, 2023 at 9:10 A.M. Eastern Time in Boston, MA.

ONI, the biotechnology company broadly enabling the ability to observe single molecules in living cells with its desktop Nanoimager microscopy platform, announced that Paul Scagnetti has been appointed as the company’s new CEO, effective February 27, 2023.

IMUNON, Inc.(NASDAQ: IMNN), a clinical-stage biotechnology company, and Break Through Cancer, a public foundation dedicated to empowering outstanding researchers and clinicians to both intercept and find cures for some of the most difficult-to-treat cancers, announces the commencement of patient enrollment in a collaboration to evaluate IMUNON’s IMNN-001 (formerly GEN-1) in combination with bevacizumab in patients with advanced ovarian cancer.